Close Menu

Diagnostics Business, Policy & Funding

Breaking news on Diagnostics business, policy & funding.

The company said it anticipates using about $25 million to $30 million of the net proceeds for the continued development of its KidneyIntelX platform.

First Genetics will market its F-Genetics NGS System and IVD assays to Russian laboratories for reproductive health testing and cancer diagnostics.

The company said it has signed a US distribution agreement for its COVID-19 test with an undisclosed strategic partner.

Vela Diagnostics said that the RT-PCR-based test has also received provisional authorization from the Health Sciences Authority in Singapore.

OpGen will promote the system for the enrichment of circulating endothelial cells from whole blood, which could be useful for COVID-19 research.